Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) ORF54 encodes a functional dUTPase expressed in the lytic replication cycle

E Kremmer, P Sommer, D Holzer, SA Galetsky, VA Molochkov, V Gurtsevitch, C Winkelmann, R Lisner, G Niedobitek and FA Grasser GSF-Institut fur Molekulare Immunologie, Marchioninistr. 25, 81377 Munchen, Germany The complete ORF54 of the Kaposi's sarcoma-associated herpesvirus (KSHV) (human herpes...

Full description

Saved in:
Bibliographic Details
Published inJournal of general virology Vol. 80; no. 5; pp. 1305 - 1310
Main Authors Kremmer, E, Sommer, P, Holzer, D, Galetsky, SA, Molochkov, VA, Gurtsevitch, V, Winkelmann, C, Lisner, R, Niedobitek, G, Grasser, FA
Format Journal Article
LanguageEnglish
Published England Soc General Microbiol 01.05.1999
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:E Kremmer, P Sommer, D Holzer, SA Galetsky, VA Molochkov, V Gurtsevitch, C Winkelmann, R Lisner, G Niedobitek and FA Grasser GSF-Institut fur Molekulare Immunologie, Marchioninistr. 25, 81377 Munchen, Germany The complete ORF54 of the Kaposi's sarcoma-associated herpesvirus (KSHV) (human herpesvirus-8; HHV-8) was cloned and expressed in E. coli. The results show that KSHV/HHV-8 ORF54 encodes a functional dUTPase which specifically hydrolyses dUTP to dUMP. Monoclonal antibodies against the HHV-8 dUTPase detected a protein with the expected molecular mass of 35 kDa in HHV-8-infected BCBL-1 cells. Induction of the lytic replication cycle of HHV-8 by treatment of BCBL-1 cells with the phorbol ester TPA resulted in an increased expression of the protein which was not inhibited by phosphonoacetic acid, indicating that the protein is expressed early in the lytic replication cycle. Moreover, the sporadic expression of the HHV-8 dUTPase in tissue sections of Kaposi's sarcoma was detected by immunohistochemistry.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0022-1317
1465-2099
DOI:10.1099/0022-1317-80-5-1305